Abstract
Objective
This study aimed to investigate the relationship between leucine-rich alpha-2-glycoprotein 1 (LRG1), hepatosteatosis, and insulin resistance (IR) in obese children, and to evaluate the potential role of LRG1 as a biomarker in these metabolic conditions.
Methods
A cohort of obese and non-obese children were enrolled. Obese subjects were further grouped by hepatosteatosis and IR status. Anthropometric measurements, biochemical parameters, and inflammatory markers including LRG1, adiponectin, and tumor necrosis factor-α (TNF-α) were evaluated. Associations between these markers and metabolic parameters were analyzed.
Results
The cohort consisted of 172 children, of whom 100 (58.1%) were obese and 72 were non-obese. Obese children had significantly higher body mass index (BMI), BMI standard deviation scores, waist and upper arm circumferences, triceps skinfold thickness, total and percentage body of fat (PBF), and elevated systolic blood pressure (SBP) and diastolic blood pressure (DBP) (p<0.001). Laboratory findings revealed elevated glucose, insulin, homeostatic model assessment of IR (HOMA-IR), alanine aminotransferase, triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and lower high-density lipoprotein cholesterol (HDL-C) in the obese group (p<0.05). LRG1 levels did not differ by obesity or hepatosteatosis status but were significantly lower in those with IR (p=0.03). LRG1 was negatively correlated with waist circumference, DBP, insulin, HOMA-IR, TG, TC, and LDL-C, and positively with HDL-C (p<0.05). Adiponectin showed inverse correlations with waist circumference, SBP, insulin, HOMA-IR, TC, LDL-C, TG, and a positive correlation with HDL-C (p<0.05).
Conclusion
Findings suggest LRG1 may not serve as a direct biomarker for hepatosteatosis in obese children but was negatively associated with IR and dyslipidemia. These results highlight a complex role for LRG1 in obesity-related metabolic dysfunction and support further longitudinal and pathophysiological studies.
Keywords: LRG1, obesity, hepatosteatosis, insulin resistance, children, adipokines
Read the full text
5 sections · 4 tables · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi’i A. A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 2021;136:104754. Epub 2021 Aug 16.
Bulcão C, Ferreira SR, Giuffrida FM, Ribeiro-Filho FF. The new adipose tissue and adipocytokines. Curr Diabetes Rev. 2006;2:19-28.
Funcke JB, Scherer PE. Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J Lipid Res. 2019;60:1648-1684. Epub 2019 Jun 17.
Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339-43.
Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731-7. Epub 2002 Jun 17.
Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356-62.
Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184-223.
Askin L, Abus S, Tanriverdi O. Resistin and cardiovascular disease: a review of the current literature regarding clinical and pathological relationships. Curr Cardiol Rev. 2022;18:e290721195114.
Choi HM, Doss HM, Kim KS. Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int J Mol Sci. 2020;21:1219.
Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, Sánchez-Margalet V. Role of leptin in inflammation and vice versa. Int J Mol Sci. 2020;21:5887.
Sena CM. Omentin: a key player in glucose homeostasis, atheroprotection, and anti-inflammatory potential for cardiovascular health in obesity and diabetes Biomedicines. 2024;12:284.
Haupt H, Baudner S. Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum. Hoppe Seylers Z Physiol Chem. 1977;358:639-46.
Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, Luhmann UFO, Lange CAK, Zhai Z, Arthur HM, Bainbridge J, Moss SE, Greenwood J. LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature. 2013;499:306-11.
Wang CH, Li M, Liu LL, Zhou RY, Fu J, Zhang CZ, Yun JP. LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Oncotarget. 2015;6:42118-29. Epub 2015 Dec 8.
Zhong D, He G, Zhao S, Li J, Lang Y, Ye W, Li Y, Jiang C, Li X. LRG1 modulates invasion and migration of glioma cell lines through TGF-β signaling pathway. Acta Histochem. 2015;117:551-8. Epub 2015 Jun 3.
Pek SL, Tavintharan S, Wang X, Lim SC, Woon K, Yeoh LY, Ng X, Liu J, Sum CF. Elevation of a novel angiogenic factor, leucine-rich-α2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes. J Clin Endocrinol Metab. 2015;100:1586-93. Epub 2015 Jan 30.
Watson CJ, Ledwidge MT, Phelan D, Collier P, Byrne JC, Dunn MJ, McDonald KM, Baugh JA. Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ Heart Fail. 2011;4:188-97. Epub 2011 Jan 31.
Nakajima M, Miyajima M, Ogino I, Watanabe M, Hagiwara Y, Segawa T, Kobayashi K, Arai H. Brain localization of leucine-rich α2-glycoprotein and its role. Acta Neurochir Suppl. 2012;113:97-101.
Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T. Leucine-rich α2-glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015;67:2056-60.
Pek SLT, Cheng AKS, Lin MX, Wong MS, Chan EZL, Moh AMC, Sum CF, Lim SC, Tavintharan S. Association of circulating proinflammatory marker, leucine-rich-α2-glycoprotein (LRG1), following metabolic/bariatric surgery. Diabetes Metab Res Rev. 2018;34:e3029.
He S, Ryu J, Liu J, Luo H, Lv Y, Langlais PR, Wen J, Dong F, Sun Z, Xia W, Lynch JL, Duggirala R, Nicholson BJ, Zang M, Shi Y, Zhang F, Liu F, Bai J, Dong LQ. LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance. J Clin Invest. 2021;131:e148545.
Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Baş F. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol. 2015;7:280-93.
Rosner B, Prineas RJ, Loggie JM, Daniels SR. Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr. 1993;123:871-86.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291-303. Epub 1969 Jun 1.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-50.
Choi CHJ, Barr W, Zaman S, Model C, Park A, Koenen M, Lin Z, Szwed SK, Marchildon F, Crane A, Carroll TS, Molina H, Cohen P. LRG1 is an adipokine that promotes insulin sensitivity and suppresses inflammation. eLife. 2022;11:e81559. Epub 2022 Nov 8.
Luo L, Liu M. Adiponectin: friend or foe in obesity and inflammation. Med Rev (2021). 2022;2:349-362.
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439-51.
Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, Feldstein AE, Nobili V. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr. 2011;53:190-5.
